We joined the 2026 WEF Technology Pioneer community because better science alone won’t fix drug development.
If you want to change an entire industry, you have to be in the room with the right people.
Today, the World Economic Forum (WEF) named Parallel Bio a 2026 Technology Pioneer. That designation places us in a cohort of 100 early-stage companies selected globally for their potential to address major challenges. We're proud of the title, but what we're really excited about is what it unlocks: a seat at the table with the policymakers, investors, and global leaders who are effecting real change.
There are few people in the world today unfamiliar with the escalating crisis of rapidly increasing drug prices in the face of exponentially slower development of new medicines. The increase in drug prices and lack of new medicines is a direct result of the current methods of discovering and developing new drugs utilized by the pharmaceutical industry at large. Pharma predicts drug success in patients on rigorous animal testing, but the odds of drug success end up being about the same as betting on a single number of roulette - 2.7%. Despite this colossal failure rate, pharma hasn’t changed its process for creating and testing drugs in 90 years. Pharma keeps placing the same bad bet on animal testing, and patients are left to pay the price.
Our platform tests and develops drugs in human lymph node organoids that model how a treatment will actually perform in a real human body. The FDA is already moving in our direction, setting a 2030 target to make animal testing the exception rather than the norm in preclinical drug development. The EPA has committed to eliminating mammalian animal testing entirely by 2035. The regulatory momentum around drug approval requirements and guidance on new approach methodologies created an opening that didn't exist a decade ago, and our science is already ready to meet it.
But fixing a broken drug development system requires more than better science. It requires regulators willing to accept new standards of evidence, pharma leaders willing to run a different playbook, and investors willing to back something the industry hasn't tried at scale. The WEF Technology Pioneer program puts us in front of those people, alongside a cohort of companies selected for bringing frontier technologies to market, creating long-term societal impact and advancing the Forum's mission to improve the state of the world - a mission we at Parallel Bio deeply align with.
We’ll have more to share soon on the science and partnerships moving this forward. For now, thank you to the WEF, to our current partners and supporters, and most importantly to our team at Parallel Bio who made this possible.
